Published : Dec-2017
No. of Pages : 654
Table of Contents 3
List of Tables 13
List of Figures 19
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24
AstraZeneca Plc, Medical Devices Deals, 2011 to YTD 2017 26
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 27
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deal Details 49
Asset Purchase 49
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 49
AstraZeneca to Acquire Rights to OX-CLI Project from Orexo 50
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53
MedImmune Acquires Patent Rights and Technologies from Allozyne 55
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58
Horizon Pharma Acquires US Rights To Vimovo From Pozen 60
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 61
AstraZeneca Acquires Neuroscience Assets From Link Medicine 62
Venture Financing 63
Albireo to Raise USD10 Million in Venture Financing 63
G1 Therapeutics Raises USD47 Million in Series C Financing 64
Rani Therapeutics Raises Funds in Financing 66
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 68
G1 Therapeutics Raises USD33 Million in Series B Financing 70
Moderna Therapeutics Raises USD450 Million in Venture Financing 72
Definiens Raises USD20.3 Million in Venture Financing Round 74
ZS Pharma Raises US$55 Million In Series D Financing 75
Catabasis Pharma Raises US$32.4 Million In Series B Financing 77
G1 Therapeutics Raises US$12.5 Million In Series A Financing 79
Inotek Pharma Raises US$21 Million In Venture Financing 80
AesRx Raises US$1.35 Million In Venture Financing 82
Acerta Pharma Raises Funds through Series A Venture Financing 83
Omthera Pharma Raises US$17.6 Million In Venture Financing 84
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 85
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 87
Pearl Therapeutics Raises US$65 Million In Series D Financing 88
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 90
ZS Pharma Raises US$46 Million In Series C Financing 92
Definiens Raises US$13 Million In Venture Financing 93
Coferon Raises US$12 Million In Series B Venture Financing Round 94
ZS Pharma Secures Additional US$1 Million In Series A Financing 95
ADC Therapeutics To Raise US$50 Million In Venture Financing 96
Omthera Pharma Secures Additional US$5.1 Million In Series B Financing 98
Catabasis Pharma Secures US$8 Million In Extended Series A Financing 99
NeuProtect Secures Second Venture Financing Round 101
Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 102
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 104
Private Equity 106
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 106
Partnerships 107
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 107
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 108
AstraZeneca Forms Joint Venture with SDIC Fund 109
AstraZeneca Enters into Agreement with University of Michigan 110
AstraZeneca and MedImmune Expands Agreement with Incyte 111
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 112
Roivant Sciences Enters into Development Partnership with AstraZeneca 113
NewLink Genetics Enters into Agreement with AstraZeneca 114
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 115
BERG Enters into Research Partnership with AstraZeneca 116
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 117
Champions Oncology Enters into Agreement with AstraZeneca 118
AstraZeneca Enters into Agreement with Merck 119
MedImmune Enters into Agreement with Washington University School of Medicine 120
Pieris Pharma Enters into Development Agreement with AstraZeneca 121
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 122
Genomic Vision Enters into Partnership with AstraZeneca 123
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 124
Sanofi Enters into Co-Development Agreement with MedImmune 125
APT Therapeutics Enters into Agreement with AstraZeneca 126
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 127
Bicycle Therapeutics Enters into Agreement with AstraZeneca 128
MedImmune Enters into Co-Development Agreement with Abpro 129
AstraZeneca Enters into Co-Marketing Agreement with Aspen 130
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 131
Centre for Drug Research and Development Partners with AstraZeneca 132
Foundation Medicine Enters into Agreement with AstraZeneca 133
MedImmune Enters into Agreement with Genisphere 134
Esteve Enters into Agreement with AstraZeneca 135
Foundation Medicine Partners with AstraZeneca 136
Daewoong Pharma Enters into Agreement with AstraZeneca 137
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 138
Lipigon Pharma Enters into Research Agreement with AstraZeneca 139
PROOF Centre Partners with AstraZeneca 140
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 141
Allergan Enters into Co-Development Agreement with AstraZeneca 142
Cepheid, MedImmune and Combacte Enter into Agreement 143
Incyte Enters into Agreement with AstraZeneca 144
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 145
Rani Therapeutics Enters into Agreement with MedImmune 146
AstraZeneca Enters into Agreement with WuXi AppTec 147
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 148
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 149
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 150
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 151
Hutchison MediPharma Enters into Agreement with AstraZeneca 152
Alvogen Enters into Marketing Agreement with AstraZeneca 153
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 154
Peregrine Pharma Expands its Agreement with AstraZeneca 155
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 156
MedImmune Enters into Research Agreement with University of Sheffield 157
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 158
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 159
AstraZeneca Enters into Research Agreement with Inserm 160
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 161
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 162
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 163
AstraZeneca Expands Research Agreement with Eli Lilly 164
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 165
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 166
AstraZeneca Enters into Research Agreement with Sutter Health 167
Celgene Enters into Co-Development Agreement with MedImmune 168
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 169
MedImmune Enters into Agreement with Juno Therapeutics 170
Bina Technologies Enters into Agreement with AstraZeneca 171
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 172
PatientsLikeMe Enters into Research Agreement with AstraZeneca 173
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 174
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 175
MedImmune Enters into Research Agreement with Joslin Diabetes Center 176
Orca Pharma Enters into Development Agreement with AstraZeneca 177
MedImmune Enters into Research Agreement with University of Manchester 178
MedImmune Enters into Research Agreement with COEBP 179
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 180
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 181
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 182
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 183
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 184
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 185
MedImmune Enters into Co-Development Agreement with National Cancer Institute 186
Molplex Enters into Research Collaboration with AstraZeneca 187
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 188
AstraZeneca Partners with Biognosys 189
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 190
AstraZeneca Expands Co-Development Agreement with Isis Pharma 191
AstraZeneca Forms Joint Venture with University of Manchester 192
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 193
Cancer Research UK Forms Joint Venture with MedImmune 195
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 196
Astrazeneca Enters into Research Agreement with Redx Pharma 197
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 198
AstraZeneca Enters into Co-Development Agreement with Qiagen 199
AstraZeneca Enters into Co-Development Agreement with Roche 200
Advaxis Enters into Agreement with MedImmune 201
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 202
AstraZeneca Extends Collaboration with MRC Technology 203
AstraZeneca Extends its Co-Development Agreement with MRC 204
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 205
Gustave Roussy Enters into Research Agreement with AstraZeneca 206
AstraZeneca Forms Joint Venture with Samsung Biologics 207
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 208
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 209
MedImmune Enters Research Agreement With University of Texas MD Anderson 210
MedImmune Enters Into Research Agreement With Cambridge University 211
Biolojic Design Enters into Partnership with MedImmune 212
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 213
MedImmune Enters Into Research Agreement With Johns Hopkins University 214
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 215
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 216
AstraZeneca Enters Into Research Agreement With Lieber Institute 217
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 218
Taris BioMedical Enters Into Research Agreement With AstraZeneca 220
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 221
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 222
X-Chem Extends Drug Discovery Agreement With AstraZeneca 223
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 224
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 225
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 226
Biosortia Pharma Enters into Research Agreement with AstraZeneca 227
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 228
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 229
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 230
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 231
NeoMed Enters Into Research Agreement With AstraZeneca 232
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 233
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 234
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 235
AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 236
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 238
AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 239
AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 240
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 241
Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 242
Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 243
CytImmune Sciences and AstraZeneca Enter into Research Agreement 244
AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 245
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 246
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 247
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 248
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 249
PeptiDream Enters into Drug Discovery Agreement with MedImmune 250
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 251
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 253
Charles River Labs Expands its Agreement with AstraZeneca 254
Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 255
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 256
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 258
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 259
Starpharma Holdings Enters into Agreement with AstraZeneca 260
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 261
Knode Enters Into Co-Development Agreement With AstraZeneca 262
Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 263
AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 264
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 265
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 266
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 267
AstraZeneca Enters Into Co-Promotion Agreement With The Medicines Company For Brilinta 268
AstraZeneca And Conformetrix Enter Into Co-Development Agreement 269
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 270
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 271
Enlight Biosciences Enters Into Co-Development Agreement With AstraZeneca And Novo Nordisk 273
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 274
AgonOx Enters Into Co-Development Agreement With MedImmune 275
AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419 276
AstraZeneca Enters Into Co-Development Agreement With Heptares 278
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Denosumab 280
GlaxoSmithKline, AstraZeneca And The University Of Manchester Form Joint Venture 281
Agendia Enters Into Collaboration With AstraZeneca And The Netherlands Cancer Institute 283
Pfenex Enters Into Collaboration With MedImmune 284
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 285
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 286
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 287
Senectus Therapeutics Enters into Partnership with AstraZeneca 288
Sage Bionetworks Enters Into Collaboration With AstraZeneca 289
AstraZeneca Enters Into Research And Development Agreement With Galderma Pharma 290
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 291
AstraZeneca Enters Into Co-Development Agreement With Sarah Cannon Research Institute 293
KINAXO Biotechnologies Enters Into Collaboration With AstraZeneca 294
Merger 295
AstraZeneca Rumored To Merge With Amgen 295
Licensing Agreements 296
PhaseBio Pharma Enters into Licensing Agreement with MedImmune 296
AstraZeneca Enters into Licensing Agreement with Moderna Therapeutics 297
Mereo Biopharma Enters into Licensing Agreement with AstraZeneca 298
GamaMabs Enters into Licensing Agreement with MedImmune 299
TerSera Therapeutics Enters into Licensing Agreement with AstraZeneca for Zoladex 300
Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 301
Hongkong Sansheng Medical Enters into Licensing Agreement with AstraZeneca 302
Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 303
Insmed Enters into Licensing Agreement with AstraZeneca 304
Allergan Enters into Licensing Agreement with AstraZeneca 305
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 306
Grunenthal Enters into Licensing Agreement with AstraZeneca 307
Regeneron Pharma Enters into Licensing Agreement with MedImmune 308
ProStrakan Enters into Licensing Agreement with AstraZeneca for Moventig 309
China Medical System Enters into Licensing Agreement with AstraZeneca 310
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 311
MedImmune Enters into Licensing Agreement with Wacker Biotech 312
Valeant Pharma Amends Licensing Agreement with AstraZeneca 313
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 314
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 315
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 316
MedImmune Enters into Licensing Agreement with Inovio Pharma 317
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 318
AstraZeneca Enters into Licensing Agreement with Isis Pharma 319
Emeriti Pharma Receives Intellectual Property Rights from AstraZeneca 320
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 321
AstraZeneca Enters Into Licensing Agreement with VIB and CD3 322
Kolltan Pharma Enters into Licensing Agreement with Spirogen 323
Isis Pharma Enters Into Licensing Agreement With AstraZeneca 324
AstraZeneca Enters Into Licensing Agreement With Pfizer For Nexium 326
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 328
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 329
MedImmune To Enter Into Licensing Agreement With Pfizer 331
Sinovac Biotech Amends Licensing Agreement with MedImmune 332
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 333
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Brodalumab 334
Corvidia Therapeutics Enters into Licensing Agreement with AstraZeneca 335
AstraZeneca Enters into Licensing Agreement with Starpharma 336
AstraZeneca Enters into Licensing Agreement with Eolas Therapeutics 337
MedImmune Enters into Licensing Agreement with Omnis Pharma 338
AstraZeneca Amends Research and Licensing Agreement with Dynavax 339
Shionogi Enters into Licensing Agreement with MedImmune 341
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 342
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 343
AstraZeneca Enters Into Licensing Agreement With FOB Synthesis 344
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 345
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 347
Humabs Biomed Enters into Licensing Agreement with MedImmune 348
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 349
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 350
AstraZeneca Enters Into Licensing Agreement With X-Chem For Three Drug Discovery Programs 351
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 352
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 354
AstraZeneca Enters Into Licensing Agreement With Optibrium For StarDrop Drug Discovery Software 355
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 356
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 358
Targacept And AstraZeneca Amend Licensing Agreement For Cognitive Disorders 359
AstraZeneca Enters Into Licensing Agreement With Vanderbilt University For Neuroscience Drug Discovery 361
AstraZeneca Enters into Licensing Agreement with Vanderbilt University 362
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 363
Optimer Pharma Enters Into Licensing Agreement With AstraZeneca For Clostridium Difficile Infection Drug 364
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer's Disease 365
AstraZeneca Amends Licensing Agreement with Hutchison MediPharma for Savolitinib 366
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 368
Taj Pharma Enters Into Licensing Agreement With ASTRAZENECA Pharma For Gemcitabine HCI 369
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 370
Spirogen Enters Into Licensing Agreement With Genentech 371
Equity Offering 372
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 372
AstraZeneca Invests USD140 Million in Moderna Therapeutics 373
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 374
ZS Pharma Prices Public Offering of Shares for USD185.7 Million 375
FibroGen to Raise USD20 Million in Private Placement of Shares 376
ZS Pharma Raises USD123 Million in IPO of Shares 378
Omthera Pharma Completes IPO For US$64 Million 380
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million 382
Ardea Biosciences Completes Public Offering Of Common Stock For US$166 Million 383
Ardea Biosciences Completes Exercise Of Underwriters' Over-allotment Option For US$82 Million 385
Debt Offering 387
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 387
AstraZeneca Prices Public Offering of Notes Due 2022 for USD0.25 Billion 389
AstraZeneca Prices Public Offering of 2.375% Notes Due 2022 for USD1 Billion 390
AstraZeneca Prices Public Offering of 3.125% Notes Due 2027 for USD0.75 Billion 391
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 392
AstraZeneca Prices Public Offering of 1.25% Notes for USD912 Million 394
AstraZeneca Prices Public Offering of 0.75% Notes for USD1 Billion 395
AstraZeneca Prices Public Offering of 0.25% Notes for USD570 Million 396
AstraZeneca Prices Public Offering of Floating Rate Notes Due 2018 for USD400 Million 397
AstraZeneca Prices Public Offering of 2.375% Notes Due 2020 for USD1.6 Billion 398
AstraZeneca Prices Public Offering of 1.75% Notes Due 2018 for USD1 Billion 399
AstraZeneca Prices Public Offering of 3.375% Notes Due 2025 for USD2 Billion 400
AstraZeneca Prices Public Offering of 4.375% Notes Due 2045 for USD1 Billion 401
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 402
AstraZeneca Completes Public Offering Of Notes Due 2042 For US$1 Billion 403
AstraZeneca Completes Public Offering Of Notes Due 2019 For US$1 Billion 404
Asset Transactions 405
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 405
Avara Pharma Acquires Reims Manufacturing Facility from AstraZeneca 406
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 407
Grunenthal Acquires Rights to Zomic from AstraZeneca 408
Recordati Acquires Rights for Seloken from Astrazeneca 409
Pfizer to Acquire Neksium Brand from AstraZeneca 410
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 411
Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 413
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 414
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 416
Avara Pharma Acquires Manufacturing Facility from AstraZeneca 417
Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 418
China Medical System Acquires Rights to Imdur from AstraZeneca 420
Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 421
Genzyme Acquires Caprelsa from AstraZeneca 422
Acturum Life Science Acquires Rights to Fractalkine Project from AstraZeneca 423
Tillotts Pharma Acquires Entocort from AstraZeneca 424
IGI Labs Acquires 18 Injectable Products from AstraZeneca for USD6.5 Million 425
Clinigen Group Acquires Ethyol from AstraZeneca 426
Acturum Development Acquires Sodertalje R&D facilities of AstraZeneca 427
BiQ Pharma Acquires Research Facility from AstraZeneca 428
Alliance Pharma Acquires Antimalarial Drug Brands From AstraZeneca UK For US$8 Million 429
Acquisition 430
AstraZeneca May Acquire Acadia Pharma 430
AstraZeneca Acquires 55% Stake in Acerta Pharma 431
AstraZeneca Acquires ZS Pharma for USD2.7 Billion 432
Actelion Plans to Acquire ZS Pharma 434
AstraZeneca May Acquire Juno Therapeutics 435
Pfizer May Increase Bid to Acquire AstraZeneca 436
MedImmune Acquires Definiens for USD150 Million 438
AstraZeneca May Acquire Ariad Pharma 439
AstraZeneca Completes Acquisition Of Remaining 20% Stake In AstraZeneca K.K. From Sumitomo Chemical For US$102 Million 441
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 443
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 445
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 446
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 448
AstraZeneca Completes Acquisition Of Omthera Pharmaceuticals For Up To US$443 Million 449
AstraZeneca Completes Acquisition Of Pearl Therapeutics, Respiratory Therapies Developer, For Up To US$1.15 Billion 451
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 453
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 455
AstraZeneca Reportedly Mulls Acquisition of Shire 456
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 457
AstraZeneca Completes Sale Of Aptium Oncology For Up To US$500 Million 459
AstraZeneca Completes Acquisition Of Ardea Biosciences, Gout Drug Maker, For US$1.26 Billion 460
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 462
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 463
AstraZeneca Completes Acquisition Of Guangdong BeiKang Pharma, Generics Manufacturer 464
AstraZeneca Plc - Key Competitors 465
AstraZeneca Plc - Key Employees 466
AstraZeneca Plc - Locations And Subsidiaries 469
Head Office 469
Other Locations & Subsidiaries 469
Joint Venture 474
Recent Developments 475
Strategy And Business Planning 475
Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZeneca's BioVentureHub 475
Apr 25, 2017: AstraZeneca marks a key milestone with the topping out' of new global R&D centre and HQ in Cambridge, UK 476
Financial Announcements 478
Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 478
Jul 27, 2017: AstraZeneca Announce H1 2017 Results 486
Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 495
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 496
Nov 10, 2016: AstraZeneca: Year-To-Date and Q3 2016 Results 497
Jul 28, 2016: AstraZeneca: H1 2016 Results 509
Apr 29, 2016: AstraZeneca announces 1st Quarter 2016 Results 520
Apr 29, 2016: AstraZeneca Announces Q1 2016 Results 531
Feb 04, 2016: Full-Year and Q4 2015 Results 533
Feb 04, 2016: AstraZeneca Full-Year and Q4 2015 Results 535
Corporate Communications 548
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 548
Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 549
Aug 16, 2017: Astrazeneca Non-executive Director Retirement 551
Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 552
Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 553
May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 554
Mar 06, 2017: Changes to AstraZeneca Board of Directors 555
Jan 27, 2017: AstraZeneca announces availability of saxa / dapa FDC in UK 556
Nov 21, 2016: AstraZeneca's MedImmune completes licensing agreement with Allergan for MEDI2070 557
Nov 09, 2016: Change To Astrazeneca Board Of Directors 558
Sep 28, 2016: Change To Astrazeneca Board Of Directors 559
Government and Public Interest 560
Nov 28, 2017: CALIXAR and AstraZeneca to Publish New Insight on KCC2 Architecture and Function 560
Oct 26, 2017: AstraZeneca report finds PreciseInhale reduces the risk' of failure when developing inhaled drugs 561
Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 562
Nov 30, 2016: EPSRC Grant for Organic Synthesis with the University of York 563
Nov 02, 2016: A new role for IGF1 signalling in driving fat tissue formation in heart disease 564
Oct 28, 2016: New data shows frequent ICU admissions from severe RSV disease among preterm infants in the first three months of life 565
Oct 05, 2016: New study shows increases in RSV hospitalization among high-risk preterm infants 566
Sep 23, 2016: Innovative pancreatic research expands treatment horizons for people with type 2 diabetes 567
Sep 23, 2016: Unique molecular atlas of pancreas produced 569
Jul 25, 2016: Scientists to develop precision medicines which exploit DNA damage as treatments for cancer 570
Jun 02, 2016: Scientists tear down pancreatic cancer's defences 571
Product News 572
12/19/2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 572
12/19/2016: Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease 573
11/07/2016: Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx 574
11/06/2017: Scientists exploit leaks in blood brain barrier to treat glioblastoma 575
10/26/2016: Myriad's BRACAnalysis CDx Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib 576
10/18/2017: US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review 577
09/27/2016: Launch of LUMICEF for Psoriasis Treatment, in Japan 578
09/21/2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement 579
Sep 20, 2016: Can drag and drop cancer simulation speed up drug discovery 580
Sep 15, 2016: Opening up a treasure trove of new drug target opportunities 582
09/05/2016: A Gene Defect as a Potential Gateway for Targeted Prostate Cancer Therapy 583
Aug 23, 2016: IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer's Disease 584
Aug 11, 2017: Experimental drug trial seeks to improve treatment for lymphoma 585
07/19/2016: FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis 587
06/22/2017: NICE approves COPD treatment roflumilast for routine NHS use 588
06/15/2017: AstraZeneca Pharma India has received Marketing Authorization of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder 589
Jun 06, 2017: Genedata
